The immunosuppressant market consists of sales of immunosuppressants or anti-rejection drugs generated by companies manufacturing immunosuppressant drugs. Immunosuppressants are medicinal substances that prevent or inhibit activity in the immune system. Immunosuppressive drugs are mainly used in organ transplantation procedures and also in the treatment of certain autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and others.
The global immunosuppressants market is expected to grow from $14.9 billion in 2019 to $15.08 billion in 2020 at a compound annual growth rate (CAGR) of 1.21%. The slow growth is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $21.44 billion in 2023 at a CAGR of 12.45%.
